Abstract
Risk stratification is a key component of determining need for and extent of lipid therapy for patients with higher-risk patients receiving more intensive treatment. At present there is no validated risk scoring system for patients infected with HIV, and guidelines for the general population are applied to this patient population. As research has shown that patients living with HIV are at increased risk for cardiovascular disease, it is felt that HIV status should be considered in assessing risk. The National Lipid Association has issued recommendations for management of dyslipidemia in patients infected with HIV. Guidelines and risk stratification schemes for the general population should be followed with the added recommendation that “HIV infection may be counted as an additional ASCVD risk factor for risk stratification.”
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002; 106(25):3143–421.
Stone NJ, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014:63:2889–934.
Ginsberg HN. The 2013 ACC/AHA guidelines on the treatment of blood cholesterol: questions, questions, questions. Circ Res. 2014;114(5):761–4.
Jacobson TA, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 – executive summary. J Clin Lipidol. 2014;8(5):473–88.
Friis-Moller N, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010;17(5):491–501.
Justice AC, et al. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis. 2012;54(7):984–94.
Aberg JA, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(1):e1–34.
Lundgren JD, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med. 2008;9(2):72–81.
Falcone EL, et al. Framingham risk score and early markers of atherosclerosis in a cohort of adults infected with HIV. Antivir Ther. 2011;16(1):1–8.
Parra S, et al. Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation. HIV Med. 2010;11(4):225–31.
Law MG, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med. 2006;7(4):218–30.
Zanni MV, et al. 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS. 2014;28(14):2061–70.
Martin SS, Blumenthal RS. Concepts and controversies: the 2013 American College of Cardiology/American Heart Association risk assessment and cholesterol treatment guidelines. Ann Intern Med. 2014;160(5):356–8.
Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet. 2013;382(9907):1762–5.
Hulten E, et al. HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies. Heart. 2009;95(22):1826–35.
Hsu R, et al. Independent predictors of carotid intimal thickness differ between HIV+ and HIV- patients with respect to traditional cardiac risk factors, risk calculators, lipid subfractions, and inflammatory markers. In 7th International AIDS conference on HIV pathogenesis, treatment, and prevention. Kuala Lumpur, Malaysia 2013.
Post WS, et al. Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med. 2014;160(7):458–67.
Fichtenbaum CJ, et al. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. J Clin Lipidol. 2010;4(4):279–87.
Shikuma CM, et al. Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. AIDS Res Hum Retrovir. 2011;27(5):461–8.
Silverberg MJ, et al. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med. 2009;150(5):301–13.
Jacobson TA, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol. 2015;9(6 Suppl):S1–S122.e1.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Myerson, M. (2019). Risk Prediction. In: Myerson, M., Glesby, M. (eds) Cardiovascular Care in Patients With HIV. Springer, Cham. https://doi.org/10.1007/978-3-030-10451-1_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-10451-1_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-10450-4
Online ISBN: 978-3-030-10451-1
eBook Packages: MedicineMedicine (R0)